Home / Resource Library / UPDATED EFFICACY AND SAFETY DATA FROM AN ONGOING PHASE 1A/B TRIAL OF THE BTK DEGRADER BEXOBRUTIDEG (NX-5948) IN PATIENTS WITH CLL ACROSS LINES OF THERAPY
UPDATED EFFICACY AND SAFETY DATA FROM AN ONGOING PHASE 1A/B TRIAL OF THE BTK DEGRADER BEXOBRUTIDEG (NX-5948) IN PATIENTS WITH CLL ACROSS LINES OF THERAPY